COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study.
COVID-19
Omicron
heart failure
severe course
vaccination
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
07
2022
accepted:
05
10
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Heart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of the COVID-19 vaccine with or without a booster (i.e., after the third dose) during the Omicron variant wave. Chronic heart failure patients in the Czech Republic were included in the analysis. COVID-19 infection was monitored from January 1st 2022 to March 31st 2022. The analysis was conducted on data collected in the National Health Information System. Vaccine effectiveness of vaccinated (with or without booster) vs. unvaccinated patients was analyzed for incidence of COVID-19, COVID-19-related hospitalizations, COVID-19 related intensive care unit admissions, and COVID-19 related mechanical ventilation/extracorporeal membrane oxygenation treatment. From a total 165,453 HF patients in the Czech Republic, 9,728 contracted COVID-19 (22.9% of them not vaccinated, 23.2% vaccinated and 53.8% vaccinated and boosted). Risk of intensive care unit (ICU) hospitalization was 7.6% in the unvaccinated group, 4.8% in the vaccinated group and 2.9% in the boosted group. The calculated effectiveness of the COVID-19 vaccine in prevention of ICU hospitalization in the vaccinated group was 41.9 and 76.6% in the boosted group. The results demonstrated moderate vaccine effectiveness in the prevention of severe COVID-19 in vaccinated but not boosted HF patients. Much stronger effectiveness was found in those who were vaccinated and boosted.
Sections du résumé
Background
UNASSIGNED
Heart failure (HF) patients are at higher risk of severe coronavirus disease 2019 (COVID-19). The Omicron variant has many novel mutations including those in the spike protein, leading to questions about vaccine effectiveness. The aim of this analysis was to evaluate the effectiveness of the COVID-19 vaccine with or without a booster (i.e., after the third dose) during the Omicron variant wave.
Methods
UNASSIGNED
Chronic heart failure patients in the Czech Republic were included in the analysis. COVID-19 infection was monitored from January 1st 2022 to March 31st 2022. The analysis was conducted on data collected in the National Health Information System. Vaccine effectiveness of vaccinated (with or without booster) vs. unvaccinated patients was analyzed for incidence of COVID-19, COVID-19-related hospitalizations, COVID-19 related intensive care unit admissions, and COVID-19 related mechanical ventilation/extracorporeal membrane oxygenation treatment.
Findings
UNASSIGNED
From a total 165,453 HF patients in the Czech Republic, 9,728 contracted COVID-19 (22.9% of them not vaccinated, 23.2% vaccinated and 53.8% vaccinated and boosted). Risk of intensive care unit (ICU) hospitalization was 7.6% in the unvaccinated group, 4.8% in the vaccinated group and 2.9% in the boosted group. The calculated effectiveness of the COVID-19 vaccine in prevention of ICU hospitalization in the vaccinated group was 41.9 and 76.6% in the boosted group.
Interpretation
UNASSIGNED
The results demonstrated moderate vaccine effectiveness in the prevention of severe COVID-19 in vaccinated but not boosted HF patients. Much stronger effectiveness was found in those who were vaccinated and boosted.
Identifiants
pubmed: 36337877
doi: 10.3389/fcvm.2022.998842
pmc: PMC9631812
doi:
Types de publication
Journal Article
Langues
eng
Pagination
998842Informations de copyright
Copyright © 2022 Parenica, Benesova, Radvan, Sanca, Hlasensky, Lokaj, Ondrus, Helanova, Kala, Dusek and Jarkovsky.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMJ Open. 2021 Feb 23;11(2):e045442
pubmed: 33622955
MMWR Morb Mortal Wkly Rep. 2022 Jan 21;71(4):139-145
pubmed: 35085224
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Nat Rev Microbiol. 2021 Jul;19(7):409-424
pubmed: 34075212
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Cardiovasc Res. 2022 Jun 22;118(7):1618-1666
pubmed: 34864876
Cell. 2021 Apr 15;184(8):2201-2211.e7
pubmed: 33743891
Eur J Heart Fail. 2017 Feb;19(2):201-208
pubmed: 27790819
Eur J Prev Cardiol. 2020 Dec;27(2_suppl):46-51
pubmed: 33238736
Eur J Epidemiol. 2022 Feb;37(2):157-165
pubmed: 35083602
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
PLoS Med. 2022 Sep 1;19(9):e1003992
pubmed: 36048766
Nat Commun. 2022 Sep 30;13(1):5736
pubmed: 36180428
Front Endocrinol (Lausanne). 2022 May 02;13:876028
pubmed: 35586628
MedComm (2020). 2021 Dec 16;2(4):838-845
pubmed: 34957469
Int J Cardiol. 2022 Sep 15;363:111-118
pubmed: 35728700
MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):459-465
pubmed: 35324878
J Am Coll Cardiol. 2020 Nov 17;76(20):2334-2348
pubmed: 33129663
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Lancet Reg Health Eur. 2021 Sep;8:100158
pubmed: 34308411
N Engl J Med. 2021 Dec 16;385(25):2348-2360
pubmed: 34587382
Am Heart J. 2022 Aug;250:23-28
pubmed: 35525261
PLoS One. 2020 Aug 27;15(8):e0238281
pubmed: 32853230
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Front Immunol. 2022 Jan 24;12:830527
pubmed: 35140714
Heart Lung. 2021 Sep-Oct;50(5):587-588
pubmed: 34090175
N Engl J Med. 2022 Feb 10;386(6):531-543
pubmed: 34910859
Lancet Infect Dis. 2022 Jul;22(7):931-933
pubmed: 35623379
Environ Monit Assess. 2020 May 3;192(6):325
pubmed: 32363409